ArticleMedicina (Kaunas, Lithuania)2025

Exploring the Potential of a P2X3 Receptor Antagonist: Gefapixant in the Management of Persistent Cough Associated with Interstitial Lung Disease.

Tomoyuki Takahashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.